Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | HTR2C | P28335 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27163106 | 0.93 | APLNR (0.86) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL7768853 | 0.92 | APLNR (0.86) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL21159301 | 0.91 | APLNR (0.83) | APLNRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12522890 | 0.91 | APLNR (0.83) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL28318209 | 0.89 | APLNR (0.80) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL6099643 | 0.89 | APLNR (0.80) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL8880359 | 0.88 | APLNR (0.78) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL18256578 | 0.88 | APLNR (0.77) | APLNRHTR2AHTR2CMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11092397 | 0.87 | APLNR (0.76) | APLNRHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL680457 | 0.86 | APLNR (0.76) | APLNRHTR2AHTR2CMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409556-B | Preparation method of 3, 4-disubstituted-2-aminobenzaldehyde | 兰州康鹏威耳化工有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-116706230-B | High-voltage electrolyte for lithium battery | 浙江大学 | 2024-02-02 | — | — | CN | claimed |
| CN-116706230-A | High-voltage electrolyte for lithium battery | 浙江大学 | 2023-09-05 | — | — | CN | claimed |
| CN-114409556-A | Preparation method of 3, 4-disubstituted-2-aminobenzaldehyde | 兰州康鹏威耳化工有限公司 | 2022-04-29 | — | — | CN | claimed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-12624011-B2 | Oxadiazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-05-12 | — | — | US | disclosed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731306-A1 | CYSTOBACTAMID DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-12590096-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists | BeOne Medicines | GmbH (CH) | 2026-03-31 | — | — | US | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2002018031-A2 | A DEVICE AND METHOD FOR REMOVING PARTICULATE MATERIAL FROM SUSPENSIONS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6143917-A | FROM A DIARYL CARBONATE AND AN AMINE COMPOUND HAVING AT LEAST ONE HYDROGEN ATOM LOCATED AT AN N-POSITION UNDER MODERATE CONDITIONS AT A HIGH REACTION RATE WITH A HIGH SELECTIVITY AND WITH A HIGH YIELD | UBE INDUSTRIES, LTD. (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0902014-A1 | PROCESS FOR PRODUCING ARYL CARBAMATES | UBE INDUSTRIES LIMITED (JP) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | APLNR 1947/4885HTR2A 3715/4885HTR2C 4428/4885 |
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | APLNR 4079/4885HTR2A 3582/4885HTR2C 1891/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | APLNR 1033/4885HTR2A 4096/4885HTR2C 4529/4885 |
| US-12624011-B2 | Oxadiazole derivative | HSD3B1, CBR3, CBR1 | APLNR 4811/4885HTR2A 1896/4885HTR2C 837/4885 |
| US-12590096-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists | TLR8, TLR7, TLR1 | APLNR 80/4885HTR2A 337/4885HTR2C 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.